Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

 
• By Joseph Haas

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

2023 AASLD
Three firms developing FGF21 analogs for NASH made their cases at AASLD • Source: Scrip

More from Strategy

More from Business